Is urinary indolyl-3-acryloylglycine a biomarker for autism with gastrointestinal symptoms?

References

• Adams-Chapman I, Stoll BJ. (2006). Neonatal infection and long-term neurodevelopmental outcome in the preterm infant. Curr Opin Infect Dis 19:290–7.
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. (2000). Diagnostic and statistical manual of mental disorders (4th edn, DSM-IV). Washington, DC: American Psychiatric Press.
   Google Scholar
• Bacchelli E, Maestrini E. (2006). Autism spectrum disorders: molecular genetic advances. Am J Med Genet 142C:13–23.
   PubMedGoogle Scholar
• Baird G, Simonoff E, Pickles A, Chandler S, Loucas T, Meldrum D, Charman T. (2006). Prevalence of disorders of the autism spectrum in a population cohort of children in South Thames: the Special Needs and Autism Project (SNAP). Lancet 368:210–15.
   PubMed Web of Science ®Google Scholar
• Baron-Cohen S, Scott FJ, Allison C, Williams J, Bolton P, Matthews FE, Brayne C. (2009). Prevalence of autism- spectrum conditions: UK school-based population study. Br J Psychiatry 194:500–9.
   PubMed Web of Science ®Google Scholar
• Bull G, Shattock P, Whiteley P, Anderson R, Groundwater PW, Lough JW, Lees G. (2003). Indolyl-3-acryloylglycine (IAG) is a putative diagnostic urinary marker for autism spectrum disorders. Med Sci Monit 9:422–5.
   Google Scholar
• Centers for Disease Control and Prevention. (2009). How common are autism spectrum disorders (ASD)? Available at: http://www.cdc.gov/ncbddd/autism/faq_prevalence.htm#whatisprevalence [last accessed 24 July 2009].
   Google Scholar
• Charman T. (2008). Autism spectrum disorders. Psychiatry 7:331–4.
   Google Scholar
• Ehlers S, Gillberg C, Wing L. (1999). A screening questionnaire for Asperger syndrome and other high-functioning autism spectrum disorders in school age children. J Autism Dev Disord 29:129–41.
   PubMed Web of Science ®Google Scholar
• Erickson CA, Stigler KA, Corkins MR, Posey DJ, Fitzgerald JF, McDougle CJ. (2005). Gastrointestinal factors in autistic disorder: a critical review. J Autism Dev Disord 35:713–27.
   PubMed Web of Science ®Google Scholar
• Fombonne E. (2005). Epidemiology of autistic disorder and other pervasive developmental disorders. J Clin Psychiatry 66:3–8.
   PubMed Web of Science ®Google Scholar
• Goodwin MS, Goodwin TC, Cowen MA. (1971). Malabsorption and cerebral dysfunction: a multivariate and comparative study of autistic children. J Autism Childhood Schizophrenia 1:48–62.
   PubMedGoogle Scholar
• Horvath K, Papadimitriou JC, Rabsztyn A, Drachenberg C, Tildon JT. (1999). Gastrointestinal abnormalities in children with autistic disorder. J Pediatr 135:559–63.
   PubMed Web of Science ®Google Scholar
• Horvath K, Perman JA. (2002a). Autism and gastrointestinal symptoms. Curr Gastroenterol Rep 4:251–8.
   PubMedGoogle Scholar
• Horvath K, Perman JA. (2002b). Autistic disorder and gastrointestinal disease. Curr Opin Pediatr 14:583–7.
   PubMed Web of Science ®Google Scholar
• Jepson JB. (1978). Hartnup disease. In: Stanbury JB, Wyngaarden JB, Fredrickson DS, editors. The Metabolic Basis of Inherited Disease. New York: McGraw-Hill, Inc. p. 1563–77.
   Google Scholar
• MacDermott S, Williams K, Ridley G, Glasson E, Wray J. (2007). The prevalence of autism in Australia. Can it be established from existing data? Australian Advisory Board on Autism Spectrum Disorders. Sydney, Australia.
   Google Scholar
• Marklova E, Hais IM. (1978). Age variations of indolyl-3- acryloylglycine excretion in healthy children. Sb Ved Pr Lek Fak Karlovy University Hradci Kralove 21:521–5.
   PubMedGoogle Scholar
• Marklova E, Malina L, Hais IM. (1975). Urinary excretion of indolyl-3-acryloylglycine in some skin affections. Clin Chim Acta 64:273–80.
   PubMedGoogle Scholar
• Millward C, Ferriter M, Calver S, Connell-Jones G. (2008). Gluten- and casein-free diets for autistic spectrum disorder. Cochrane Database of Systematic Reviews 2:CD003498.
   Google Scholar
• Molloy CA, Manning-Courtney P. (2003). Prevalence of chronic gastrointestinal symptoms in children with autism and autistic spectrum disorders. Autism 7:165–71.
   PubMed Web of Science ®Google Scholar
• Muhle R, Trentacoste SV, Rapin I. (2004). The genetics of autism. Pediatrics 113:e472–86.
   PubMed Web of Science ®Google Scholar
• Reichelt WH, Knivsberg AM, Nødland M, Stensrud M, Reichelt KL. (1997). Urinary peptide levels and patterns in autistic children from seven countries, and the effect of dietary intervention after 4 years. Dev Brain Dysfunct 10:44–55.
   Google Scholar
• Sandler RH, Finegold SM, Bolte ER, Buchanan CP, Maxwell AP, Väisänen ML, Nelson MN, Wexler HM. (2000). Short-term benefit from oral vancomycin treatment of regressive-onset autism. J Child Neurol 15:429–35.
   PubMed Web of Science ®Google Scholar
• Schopler E, Reichler RJ, DeVellis RF, Daly K. (1980). Toward objective classification of childhood autism: Childhood autism rating scale (CARS). J Autism Dev Disord 10:91–103.
   PubMed Web of Science ®Google Scholar
• Shattock P, Whiteley P. (2002). Biochemical aspects in autism spectrum disorders: updating the opioid-excess theory and presenting new opportunities for biomedical intervention. Expert Opin Ther Targets 6:175–83.
   PubMedGoogle Scholar
• Turk J, Bax M, Williams C, Amin P, Eriksson M, Gillberg C. (2009). Autism spectrum disorder in children with and without epilepsy: impact on social functioning and communication. Acta Paediatr 98:675–81.
   PubMed Web of Science ®Google Scholar
• Veenstra-VanderWeele J, Cook EH Jr. (2004). Molecular genetics of autism spectrum disorder. Mol Psychiatr 9:819–32.
   PubMed Web of Science ®Google Scholar
• Verhagen AR, Burbach JP. (1966). Indolyl-3-acryloylglycine and the ‘light band’ in chronic polymorphous light dermatosis. Dermatologica 133:349–65.
   PubMedGoogle Scholar
• Walker-Smith J, Andrews J. (1972). Alpha-1-antitrypsin, autism, and coeliac disease. Lancet 2:883–4.
   PubMedGoogle Scholar
• Wang J, Nation RL, Evans AM, Cox S, Li J. (2006). Determination of antiviral nucleoside analogues AM365 and AM188 in perfusate and bile of the isolated perfused rat liver using HPLC. Biomed Chromatogr 20:244–50.
   PubMedGoogle Scholar
• Whiteley P, Shattock P. (2003). What makes trans-indolyl-3- acryloylglycine identified by high-performance liquid chromatography relevant to pervasive developmental disorders? J Nutr Environ Med 13:231–7.
   Google Scholar
• Whiteley P, Rodgers J, Savery D, Shattock P. (1999). A gluten-free diet as an intervention for autism and associated spectrum disorders: preliminary findings. Autism 3:45–65.
   Google Scholar
• Whiteley P, Waring R, Williams L, Klovrza L, Nolan F, Smith S, Farrow M, Dodou K, Lough WJ, Shattock P. (2006). Spot urinary creatinine excretion in pervasive developmental disorders. Pediatr Int 48:292–7.
   PubMed Web of Science ®Google Scholar
• Wright B, Brzozowski AM, Calvert E, Farnworth H, Goodall DM, Holbrook I, Imrie G, Jordan J, Kelly A, Miles J, Smith R, Town J. (2005). Is the presence of urinary indolyl-3-acryloylglycine associated with autism spectrum disorder? Dev Med Child Neurol 47:190–2.
   PubMed Web of Science ®Google Scholar